טוען...

Predictive value and clinical utility of centrally-assessed ER, PgR and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

PURPOSE: The SOFT and TEXT randomized phase III trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) early breast cancer. We investigated the prognostic and predictive value of centrally-assessed levels of estrogen receptor (ER), progesterone...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Breast Cancer Res Treat
Main Authors: Regan, Meredith M., Pagani, Olivia, Francis, Prudence A., Fleming, Gini F., Walley, Barbara A., Kammler, Roswitha, Dell'Orto, Patrizia, Russo, Leila, Szőke, János, Doimi, Franco, Villani, Laura, Pizzolitto, Stefano, Öhlschlegel, Christian, Sessa, Fausto, Cámara, Vicente Peg, Peralto, José Luis Rodríguez, MacGrogan, Gaëtan, Colleoni, Marco, Goldhirsch, Aron, Price, Karen N., Coates, Alan S., Gelber, Richard D., Viale, Giuseppe
פורמט: Artigo
שפה:Inglês
יצא לאור: 2015
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4749471/
https://ncbi.nlm.nih.gov/pubmed/26493064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3612-z
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!